Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).

被引：0
|
作者：
Ozguroglu, Mustafa [1 ]
Alva, Ajjai Shivaram [2 ]
Csoszi, Tibor [3 ]
Matsubara, Nobuaki [4 ]
Geczi, Lajos [5 ]
Cheng, Susanna Y. [6 ]
Fradet, Yves [7 ]
Oudard, Stephane [8 ]
Vulsteke, Christof [9 ]
Morales-Barrera, Rafael [10 ]
Flechon, Aude [11 ]
Gunduz, Seyda [12 ]
Loriot, Yohann [13 ]
Rodriguez-Vida, Alejo [14 ]
Mamtani, Ronac [15 ]
Yu, Evan Y. [16 ]
Nam, Kijoeng [17 ]
Imai, Kentaro [17 ]
Moreno, Blanca Homet [17 ]
Powles, Thomas [18 ]
机构：
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey
[2] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA
[3] Hetenyi G Korhaz, Szolnok, Hungary
[4] Natl Canc Ctr Hosp East, Div Breast & Med Oncol, Chiba, Japan
[5] Natl Inst Oncol, Budapest, Hungary
[6] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[7] Univ Laval, CHU Quebec, Quebec City, PQ, Canada
[8] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Oncol, Paris, France
[9] Univ Antwerp, Integrated Canc Ctr Ghent, Ctr Oncol Res CORE, Ghent, Belgium
[10] Vall dHebron Inst Oncol, Barcelona, Spain
[11] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[12] Akdeniz Univ, Antalya, Turkey
[13] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[14] Hosp del Mar Res Inst, Dept Med Oncol, Barcelona, Spain
[15] Univ Penn, Philadelphia, PA 19104 USA
[16] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[17] Merck & Co Inc, Kenilworth, NJ USA
[18] Queen Mary Univ London, Barts Canc Inst, Barts Expt Canc Med Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.448
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
448
引用
收藏
页数：4
相关论文
共 50 条
  • [31] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
    Reck, M.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M. E.
    Rao, S.
    Hotta, K.
    Leiby, M.
    Lubiniecki, G.
    Shentu, Y.
    Rangwala, R.
    Brahmer, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
    Oh, D-Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Li, J.
    Luo, S.
    Pan, H.
    Qu, Y.
    Lu, J.
    Yang, L.
    Yasui, H.
    Yabusaki, H.
    Yen, C. J.
    Chan, W. W. L.
    Yamaguchi, K.
    Yeh, K-H.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1526
  • [33] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.
    Powles, Thomas
    Plimack, Elizabeth R.
    Stus, Viktor
    Waddell, Tom
    Gafanov, Rustem
    Pouliot, Frederic
    Nosov, Dmitry
    Melichar, Bohuslav
    Soulieres, Denis
    Borchiellini, Delphine
    Vynnychenko, Ihor
    McDermott, Raymond S.
    Azevedo, Sergio Jobim
    Tamada, Satoshi
    Kryzhanivska, Anna
    Li, Chenxiang
    Burgents, Joseph E.
    Molife, L. Rhoda
    Rini, Brian I.
    Bedke, Jens
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Lowery, M.
    Wyrwicz, L.
    Oh, D-Y.
    Shiu, K. K.
    Weber, P. Yanez
    Bai, Y.
    Lee, J.
    Rivera, F.
    Alves, G.
    Garrido, M.
    Fernandez, M. Gonzalez
    Li, J.
    Cil, T.
    Cruz, F.
    Qin, S.
    Yin, L.
    Valderrama, A.
    Bordia, S.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S854 - S855
  • [35] Niraparib (Nira) plus Pembrolizumab (Pembro) Versus Placebo (PBO) plus Pembro first line (1L) Maintenance Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): ZEAL-1L Phase 3 Study
    Schuler, Martin
    Ramalingam, Suresh S.
    Shi, Lei
    Neibauer, Melissa Whipple
    Frenkl, Tara
    Stojadinovic, Alexander
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 152 - 152
  • [36] Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
    Mok, T. S. K.
    Wu, Y-L.
    Kudaba, I.
    Kowalski, D. M.
    Cho, B. C.
    Turna, H. Z.
    de Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K. K.
    Bondarenko, I.
    Kubota, K.
    Caglevic, C.
    Karaszewska, B.
    Dang, T.
    Yin, L.
    Penrod, J.
    Lopes, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [37] Pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
    Rha, Sun Young
    Wyrwicz, Lucjan S.
    Weber, Patricio Eduardo Yanez
    Bai, Yuxian
    Ryu, Min-Hee
    Lee, Jeeyun
    Rivera, Fernando
    Alves, Gustavo Vasconcelos
    Garrido, Marcelo
    Shiu, Kai-Keen
    Fernandez, Manuel Gonzalez
    Li, Jin
    Lowery, Maeve Aine
    Cil, Timucin
    Cruz, Felipe Melo
    Oh, Do-Youn
    Yin, Lina
    Bordia, Sonal
    Bhagia, Pooja
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [39] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib (ola) vs pembro plus chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
    Saji, S.
    Cussac, A. Llombart
    Andre, F.
    Robson, M. E.
    Harbeck, N.
    Schmid, P.
    Cescon, D. W.
    Ahn, J. S.
    Nanda, R.
    Fan, L.
    Mejia, J. A.
    Karantza, V.
    Bardia, A.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1268 - S1268
  • [40] Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.
    Powles, Thomas
    Bellmunt, Joaquim
    Petrylak, Daniel Peter
    Fong, Lawrence
    Nishiyama, Hiroyuki
    Sternberg, Cora N.
    Chen, Mei
    Pang, Lei
    Munteanu, Mihaela
    Zhao, Yufan
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345